Polycystic ovaries: problematics, etiology, pathogenesis (literary review)

Abstract

The polycystic ovary syndrome (POS) is a common hormonal disorder in women all over the world; it is characterized not only by reproductive disturbances but by endocrine and metabolic as well. Women with POS are subjected to an increased risk for the development of type 2 diabetes mellitus, metabolic syndrome and sterility. This article presents information on POS problems, its history. The main etiological factors predisposing to the development of polycystic ovaries syndrome are highlighted. Besides, actual data on pathogenetic theories of POS development are presented.

Keywords

polycystic ovary syndrome / hyperandrogenia / hirsutism / sterility / acne / anovulation

References

[1] Goodman N.F., Cobin R.H., Futterweit W. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1. AACE/ACE Disease state clinical review 2015; 21 (11): 1129–1300.

[2] Goodman N.F, Cobin R.H., Futterweit W. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome – Part 1. AACE/ACE Disease state clinical review. 2015; 21 (11): 1129–1300.

[3] Renate K., Meier M.S. Polycystic Ovary Syndrome. Nursing Clinics of North America 2018; 53 (3): 407–420.

[4] Renate K., Meier M.S. Polycystic Ovary Syndrome. Nursing Clinics of North America. 2018; 53 (3): 407–420.

[5] Grodnitskaya E.E, Il'ina N.A., Dovzhenko T.V., Latyshkevich O.A., Kurtser M.A., Mel'nichenko G.A. Polycystic ovary syndrome is an interdisciplinary problem. Ginekologiya Endokrinologiya 2016; 3 (120): 59–65 (in Russian).

[6] Гродницкая Е.Э, Ильина Н.А., Довженко Т.В., Латышкевич О.А., Курцер М.А., Мельниченко Г.А. Синдром поликистозных яичников – междисциплинарная проблема/ Гинекология Эндокринология. 2016; 3 (120): 59–65.

[7] Polycystic ovary syndrome: clinical guidelines. Ros. Society of Obstetricians and Gynecologists; Grew up. Association of Endocrinologists. Moscow 2021 (in Rus-sian).

[8] Синдром поликистозных яичников: клинические рекомендации. Рос. общество акушеров-гинекологов; Рос. ассоциация эндокринологов. М. 2021.

[9] Neven A., Laven J. Teede H.J., Boyle J.A. A summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines. Semin Repord Med. 2018; 36 (1): 5–12.

[10] Sosnova E.A. Polycystic ovary syndrome/ Arkhiv akusherstva i ginekologii im. V.F. Snegireva 2016; 3 (3): 116–129 (in Rus-sian).

[11] Соснова Е.А. Синдром поликистозных яичников. Архив акушерства и гинекологии им. В.Ф. Снегирева 2016; 3 (3): 116–129.

[12] Teede H.J., Misso M.L., Costello M.F., Dokras A., Laven .J, Moran L., Piltonen T., Norman R.J. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018; 110 (3): 364–379.

[13] Teede H.J., Misso M.L., Costello M.F., Dokras A., Laven J., Moran L., Piltonen T., Norman R.J. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018; 110 (3): 364–379.

[14] Artymuk N.V., Tachkova O.A. New about the pathogenesis and treatment of polycystic ovary syndrome. Mat' i ditya 2021; 4 (1) (in Russian).

[15] Артымук Н.В., Тачкова О.А, Новое о патогенезе и лечении синдрома поликистозных яичников. Мать и дитя 2021; 4 (1).

[16] Damdinova L.V., Leshchenko O.Ya. Polycystic ovary syndrome – 80 years of research and new directions in the study of this issue (literature review). Byulleten' VSNTs SO RAMN 2016; 1 (5) (in Russian).

[17] Дамдинова Л.В., Лещенко О.Я. Синдром поликистозных яичников – 80 лет исследований и новые направления в изучении данного вопроса (обзор литературы). Бюллетень ВСНЦ СО РАМН 2016; 1 (5).

[18] Gynecology: textbook. Ed. V.E. Radzinskogo, A.M. Fuksa. Moscow: GEOTAR – Media 2014; 1000 (in Russian).

[19] Гинекология: учебник. Под ред. В.Е. Радзинского, А.М. Фукса. М.: ГЭОТАР-Медиа 2014; 1000.

[20] Baisova B.I. i dr. Gynecology: textbook. Ed. G.M. Savel'evoy, V.G. Breusenko. 4th ed., Rev. and add. Moscow: GEOTAR-Media; 2012: 432 (in Russian).

[21] Баисова Б.И. и др. Гинекология: учебник. Под ред. Г.М. Савельевой, В.Г. Бреусенко. 4-е изд., перераб. и доп. М.: ГЭОТАР-Медиа 2012; 432.

[22] Rodgers R.J., Suturina L., Lizneva D. et al. Is polycystic ovary syndrome a 20th Century phenomenon? Med Hypotheses 2019; 124: 31–34.

[23] Azziz R., Adashi E.Y. Stein and Leventhal: 80 years on. Viewpoint. 2016; 214 (2): 247.

[24] Goodman N.F., Cobin R.H., Futterweit W. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome – Part 2. AACE/ACE Disease state clinical review 2015; 21 (12): 1415–1426.

[25] Rodgers R.J., Suturina L., Lizneva D. et al. Is polycystic ovary syndrome a 20th Century phenomenon? Med Hypotheses 2019; 124: 31–34.

[26] Panarina O.V., Rashidova M.A., Belen'kaya L.V., Trofimova T.A., Sholokhov L.F. Modern views on the pathogenesis of polycystic ovary syndrome (literature review). ACTA BIOMEDICA SCIENTIFICA 2017; 2 (4): 9–14 (in Russian).

[27] Goodman N.F., Cobin R.H., Futterweit W. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome – Part 2. AACE/ACE Disease state clinical review. 2015; 21 (12): 1415–1426.

[28] Milekhina S.A., Karlina V.P., Korenkov P.G. New about the etiology and pathogenesis of polycystic ovary syndrome. Process management and scientific developments 2021.

[29] Панарина О.В., Рашидова М.А., Беленькая Л.В., Трофимова Т.А., Шолохов Л.Ф. Современные представления о патогенезе синдрома поликистозных яичников (обзор литературы). ACTA BIOMEDICA SCIENTIFICA 2017; 2 (4): 9–14.

[30] Mykhalchenko K., Lizneva D., Trofimova T. et al. Genetics of polycystic ovary syndrome. Expert. Rev. Mol. Diagn. 2017; 17 (7): 723–733.

[31] Milekhina S.A., Karlina V.P., Korenkov P.G. New about the etiology and pathogenesis of polycystic ovary syndrome. Process management and scientific developments 2021.

[32] Aylamazyan E.K. Gynecology: a textbook for medical universities. 2-e ed. Saint Petersburg: SpetsLit 2013; 415 (in Russian).

[33] Mykhalchenko K., Lizneva D., Trofimova T. et al. Genetics of polycystic ovary syndrome. Expert Rev Mol Diagn. 2017; 17 (7): 723–733.

[34] Gustovarova T.A., Bril' Yu.A. Syndrome with many unknowns. Status Praesens. Ginekologiya, akusherstvo, besplodnyy brak 2018; 4 (49): 51–57 (in Russian).

[35] Айламазян Э.К. Гинекология: учебник для медицинских вузов. 2-е изд., испр. и доп. СПб.: СпецЛит 2013; 415.

[36] Di Pietro M., Pascuali N., Parborell F. et al. Ovarian angiogenesis in polycystic ovary syndrome. Reproduction 2018; 155 (5): R199– R209.

[37] Густоварова Т.А., Бриль Ю.А. Синдром со многими неизвестными. Status Praesens. Гинекология, акушерство, бесплодный брак 2018; 4 (49): 51–57.

[38] Alcazar J.L., Kudla M.J. Ovarian stromal vessels assessed by spatiotemporal image correlation-high definition flow in women with polycystic ovary syndrome: A case-control study. Ultrasound Obstet. Gynecol 2012; 40: 470–475.

[39] Di Pietro M., Pascuali N., Parborell F. et al. Ovarian angiogenesis in polycystic ovary syndrome. Reproduction 2018; 155 (5): R199–R209.

[40] Zhao X., Jiang Y., Xi H., Chen L., Feng H. Exploration of the Relationship Between Gut Microbiota and Polycystic Ovary Syndrome (PCOS): a Review. Geburtshilfe Frauenheilkd 2020; 80 (02): 161–171.

[41] Alcazar J.L., Kudla M.J. Ovarian stromal vessels assessed by spatiotemporal image correlation-high definition flow in women with polycystic ovary syndrome: A case-control study. Ultrasound Obstet. Gynecol 2012; 40: 470–475.

[42] Chernukha G.E., Udovichenko M.A., Naydukova A.A. Mechanisms of the formation of insulin resistance in polycystic ovary syndrome and the therapeutic effects of myo-inositol. Ginekologiya 2019; 11 (166): 55–60 (in Russian).

[43] Zhao X., Jiang Y., Xi H., Chen L., Feng H. Exploration of the Relationship Between Gut Microbiota and Polycystic Ovary Syndrome (PCOS): a Review. Geburtshilfe Frauenheilkd 2020; 80 (02): 161–171

[44] Bednarska S., Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What's new? Adv Clin Exp Med. 2017; 26 (2): 359–3.

[45] Чернуха Г.Е., Удовиченко М.А., Найдукова А.А. Механизмы формирования инсулинорезистентности при синдроме поликистозных яичников и терапевтические эффекты мио-инозитола. Гинекология 2019; 11 (166): 55–60.

[46] Azizova M.E. Polycystic ovary syndrome from the standpoint of modern ideas. Kazanskiy meditsinskiy zhurnal 2015; 96 (1): 77–80 (in Russian).

[47] Bednarska S., Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What's new? Adv Clin Exp Med 2017; 26 (2): 359–3.

[48] Ibragimova N.S., Ibragimov B.F., Mamadierova M.A. Polycystic Ovary Syndrome Highlights. Vestnik nauki i obrazovaniya 2021; 2 (105) (in Russian)

[49] Азизова М.Э. Синдром поликистозных яичников с позиций современных представлений. Казанский медицинский журнал 2015; 96 (1): 77–80.

[50] Shestakova I.G., Ryabinkina T.S. PCOS: a new look at the problem. Symptom Variation, Differential Diagnosis and Treatment of PCOS: A Fact Sheet. Ed. V.E. Radzinskogo. Moscow: StatusPraesens, 2015 (in Russian).

[51] Ибрагимова Н.С., Ибрагимов Б.Ф., Мамадиёрова М.А. Синдром поликистозных яичников: основные моменты. Вестник науки и образования 2021; 2 (105).

[52] Kalugina L.V. Myo-inositol: therapeutic possibilities and pregravid preparation in polycystic ovary syndrome (literature review). Reproduktivnaya endokrinologiya 2018; 4 (42): 31–32 (in Russian).

[53] Шестакова И.Г., Рябинкина Т.С. СПКЯ: новый взгляд на проблему. Многообразие симптомов, дифференциальная диагностика и лечение СПКЯ: информационный бюллетень. Под ред. В.Е. Радзинского. М.: StatusPraesens 2015.

[54] Yakovlev P.P., Kogan I.Yu. Endometrium and Polycystic Ovary Syndrome. Zhurnal akusherstva i zhenskikh bolezney 2018; 67 (4): 60–66 (in Russian).

[55] Калугина Л.В. Мио-инозитол: терапевтические возможности и прегравидарная подготовка при синдроме поликистозных яичников (обзор литературы). Репродуктивная эндокринология 2018; 4 (42): 31–32.

[56] Il'ina I.Yu. Peculiarities of treatment of patients with polycystic ovary syndrome and metabolic syndrome. Russian Journal of Woman and Child Health 2020; 3 (4) (in Russian).

[57] Яковлев П.П., Коган И.Ю. Эндометрий и синдром поликистозных яичников. Журнал акушерства и женских болезней 2018; 67 (4): 60–66.

[58] Jeanes Y.M., Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutr Res Rev. 2017; 30 (1): 97–105.

[59] Ильина И.Ю. Особенности лечения пациенток с синдромом поликистозных яичников и метаболическим синдромом. Russian Journal of Woman and Child Health 2020; 3 (4).

[60] Zhylkichieva Ch.S., Tukhvatshin R.R., Askerov A.A. Polycystic ovary syndrome: a modern perspective on the problem. Vestnik KGMA im. I.K. Akhunbaeva 2016; 6: 47–52 (in Russian).

[61] Jeanes Y.M., Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutr Res Rev. 2017; 30 (1): 97–105.

[62] Rocha A., Oliveira F., Azevedo R., Silva V. Recent advances in the understanding and management of polycystic ovary syndrome. F1000Research. 2019; 8.

[63] Жылкичиева Ч.С., Тухватшин Р.Р., Аскеров А.А. Синдром поликистозных яичников: современный взгляд на проблему. Вестник КГМА им. И.К. Ахунбаева 2016; 6: 47–52.

[64] Zaslavskiy D.V., Prokopenko A.D., Danielyan D.A. Dermatological aspect of the significance of hyperandrogenism in polycystic ovary syndrome. Sovremenney problemy nauki i obrazovaniya 2018; 4 (in Russian).

[65] Rocha A., Oliveira F., Azevedo R., Silva V. Recent advances in the understanding and management of polycystic ovary syndrome. F1000Research 2019; 8.

[66] Blesmanovich A.E., Petrov Yu.A., Alekhina A.G. Polycystic ovary syndrome: classics and modern nuances. The Journal of scientific articles «Health and Education Millenium» 2018; 20 (4): 33–37 (in Russian).

[67] Заславский Д.В., Прокопенко А.Д., Даниелян Д.А. Дерматологический аспект значения гиперандрогении при синдроме поликистозных яичников. Современные проблемы науки и образования 2018; 4.

[68] Zhao L., Guo Y., Qi Y., Yang X., Wen S., Liu Y., Tang L. Association between Polycystic Ovary Syndrome and Gut Microbiota. PLoS ONE, 2016; 11 (4).

[69] Блесманович А.Е., Петров Ю.А., Алехина А.Г. Синдром поликистозных яичников: классика и современные нюансы. The Journal of scientific articles «Health and Education Millenium» 2018; 20 (4): 33–37.

[70] Tremellen K., Pearce K. (2012) Dysbiosis of Gut Microbiota (DOGMA) – a novel theory for the development of Polycystic Ovarian Syndrome. Medical Hypotheses 2012; 79 (1).

[71] Zhao L, Guo Y., Qi Y., Yang X., Wen S., Liu Y., Tang L. Association between Polycystic Ovary Syndrome and Gut Microbiota. PLoS ONE 2016; 11 (4).

[72] Chernukha G.E., Miroshina E.D., Priputnevich T.V. Polycystic Ovary Syndrome and Gut Microbiota. Akusherstvo i Ginekologiya 2021; 3 (in Russian).

[73] Tremellen K., Pearce K. Dysbiosis of Gut Microbiota (DOGMA) – a novel theory for the development of Polycystic Ovarian Syndrome. Medical Hypotheses 2012; 79 (1): 104.

[74] Jobira B., Frank D.N., Pyle L., Silveira L.J. Obese Adolescents With PCOS Have Altered Biodiversity and Relative Abundance in Gastrointestinal Microbiota. The Journal of Clinical Endocrinology & Metabolism 2020; 105 (6): 2134-2144.

[75] Чернуха Г.Е., Мирошина Е.Д. Припутневич Т.В. Синдром поликистозных яичников и микробиота кишечника. Акушерство и Гинекология 2021; 3.

[76] Liu R., Zhang C., Shi Y. Microbiota Associated with Clinical Parameters in Polycystic Ovary Syndrome. Front. Microbiol. 2017; 28.

[77] Jobira B., Frank D.N., Pyle L., Silveira L.J. Obese Adolescents With PCOS Have Altered Biodiversity and Relative Abundance in Gastrointestinal Microbiota, The Journal of Clinical Endocrinology & Metabolism 2020; 105 (6): 2134–2144.

[78] Ma T., Cui P., Tong X., Hu W. Ovarian Angiogenesis in Polycystic Ovary Syndrome-Like Rats Induced by Low-Frequency Electro-Acupuncture: The CLARITY Three-Dimensional Approach. Int. J. Mol. Sci. 2018; 19 (11): 3500.

[79] Liu R., Zhang C., Shi Y. Microbiota Associated with Clinical Parameters in Polycystic Ovary Syndrome. Front. Microbiol. 2017; 28.

[80] Wei J., Zhao Y. MiR-185-5p Protects Against Angiogenesis in Polycystic Ovary Syndrome by Targeting VEGFA. Front. Pharmacol 2020; 15.

[81] Ma T., Cui P., Tong X., Hu W. Ovarian Angiogenesis in Polycystic Ovary Syndrome-Like Rats Induced by Low-Frequency Electro-Acupuncture: The CLARITY Three-Dimensional Approach. Int. J. Mol. Sci. 2018; 19 (11): 3500.

[82] Tal R., Seifer D.B., Arici A. The Emerging Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome. Semin Reprod Med 2015; 33 (03): 195-207.

[83] Wei J., Zhao Y. MiR-185-5p Protects Against Angiogenesis in Polycystic Ovary Syndrome by Targeting VEGFA. Front. Pharmacol. 2020; 5.

[84] Kuzina O.V., Sosnova E.A. The value of insulin-like and vascular endothelial growth factors in the pathogenesis of polycystic ovary syndrome (literature review). Arkhiv akusherstva i ginekologii im. V.F. Snegireva 2019; 6 (2) (in Russian).

[85] Tal R., Seifer D.B., Arici A. The Emerging Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome. Semin. Reprod. Med. 2015; 33 (03): 195–207.

[86] Podzolkova N.M., Koloda Yu.A. Modern understanding of polycystic ovary syndrome. FARMATEKA dlya praktikuyushchikh vrachey 2016; 3 (in Russian).

[87] Кузина О.В., Соснова Е.А. Значение инсулиноподобного и сосудисто-эндотелиального факторов роста в патогенезе синдрома поликистозных яичников (обзор литературы). Архив акушерства и гинекологии им. В.Ф. Снегирева 2019; 6 (2).

[88] Pietro M., Parborell F. Metformin Regulates Ovarian Angiogenesis and Follicular Development in a Female Polycystic Ovary Syndrome Rat Model. Endocrinology 2015; 156 (4): 1453-1463.

[89] Подзолкова Н.М., Колода Ю.А. Современные представления о синдроме поликистозных яичников. ФАРМАТЕКА для практикующих врачей 2016; 3.

[90] Bahramrezaie M. et al. Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial. J Assist Reprod Genet 2019; 36: 1701-1712.

[91] Pietro M., Parborell F. Metformin Regulates Ovarian Angiogenesis and Follicular Development in a Female Polycystic Ovary Syndrome Rat Model. Endocrinology 2015; 156 (4): 1453–1463.

[92] Henríquez S. Significance of pro-angiogenic estrogen metabolites in normal follicular development and follicular growth arrest in polycystic ovary syndrome. Human Reproduction 2020; 35 (7): 1655-1665.

[93] Bahramrezaie M. et al. Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial. J Assist Reprod Genet. 2019; 36: 1701–1712.

[94] Patil K. Alteration in angiogenic potential of granulosa-lutein cells and follicular fluid contributes to luteal defects in polycystic ovary syndrome. Human Reproduction 2021; 36 (4): 1052-1064.

[95] Henríquez S. Significance of pro-angiogenic estrogen metabolites in normal follicular development and follicular growth arrest in polycystic ovary syndrome. Human Reproduction 2020; 35 (7): 1655–1665.

[96] Ibragimova N.S., Ibragimov B.F., Mamadierova M.A. Polycystic Ovary Syndrome Highlights. Vestnik nauki i obrazovaniya 2021; 2 (105): (in Russian).

[97] Patil K. Alteration in angiogenic potential of granulosa-lutein cells and follicular fluid contributes to luteal defects in polycystic ovary syndrome. Human Reproduction 2021; 36 (4): 1052–1064.

[98] Ибрагимова Н.С., Ибрагимов Б.Ф., Мамадиёрова М.А. Синдром поликистозных яичников: основные моменты. Вестник науки и образования 2021; 2 (105).

RIGHTS & PERMISSIONS

Bakurinskikh A.B., Yakushev A.M., Ten A.R., Kolesova A.A.